SBH
MYGN icon

Segall Bryant & Hamill’s Myriad Genetics MYGN Stock Holding History

Segall Bryant & Hamill’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-72,117
Closed -$640K – 611
2025
Q1 		$640K Hold
72,117
– – 0.01% 537
2024
Q4 		$989K Buy
72,117
+41,739
+137% +$770K 0.01% 515
2024
Q3 		$832K Buy
+30,378
New +$822K 0.01% 523
2020
Q1 		– Sell
-129,578
Closed -$3.53M – 823
2019
Q4 		$3.53M Buy
+129,578
New +$3.56M 0.05% 304

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Segall Bryant & Hamill's MYGN Position: Q2 2025 in Review

Segall Bryant & Hamill sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 72,117 shares — an estimated $640K sold.

Segall Bryant & Hamill first reported a position in MYGN in Q4 2019 and held it in 4 quarters. The position peaked at $3.53M in Q4 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Segall Bryant & Hamill reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 72,117 Myriad Genetics shares in Q2 2025, an estimated $640K.
  • Segall Bryant & Hamill first reported a position in Myriad Genetics in Q4 2019 and held it in 4 quarters.
  • Segall Bryant & Hamill's Myriad Genetics position peaked at $3.53M in Q4 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Segall Bryant & Hamill's 13F filing for Q2 2025, filed 12 Aug 2025.